NDAORALTABLET
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE (lamivudine; nevirapine; zidovudine) by Hetero is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg. First approved in 2018.
Drug data last refreshed 23h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination oral tablet containing lamivudine, nevirapine, and zidovudine for treating HIV-1 infection in adults and children weighing at least 6 kg. The combination works through multiple mechanisms: reverse transcriptase inhibition and non-nucleoside reverse transcriptase inhibition to suppress viral replication. This is a legacy antiretroviral regimen representing an earlier generation of HIV treatment.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30), suggesting stable commercial operations but potential team consolidation as newer regimens gain adoption.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE at Hetero? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.